Urinary Urgency in the Elderly

The last 2 decades have brought an explosion of research, new products, and general attention to the problem of urinary urgency, and yet patients continue to be plagued by this symptom – especially the elderly. What is it? What does it mean? How can we guide patients successfully through this challenge? This paper presents a review of current thinking about urgency relevant to the practicing clinician, including the epidemiology, pathophysiology, evaluation, and treatment of these patients.

[1]  B. Schurch,et al.  An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD) , 2018, Neurourology and urodynamics.

[2]  V. Nitti,et al.  Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis , 2017, BJU international.

[3]  J. Neuhaus,et al.  Overactive Bladder Is Strongly Associated With Frailty in Older Individuals. , 2017, Urology.

[4]  K. Andersson.  Pharmacology: Cardiovascular effects of mirabegron , 2017, Nature Reviews Urology.

[5]  M. Miyake,et al.  Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study) , 2017, Neurourology and urodynamics.

[6]  Kimberly J Angelini.  Pelvic Floor Muscle Training to Manage Overactive Bladder and Urinary Incontinence. , 2017, Nursing for women's health.

[7]  Mélanie Morin,et al.  Adult conservative management , 2017 .

[8]  H. Zyczynski,et al.  OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. , 2016, JAMA.

[9]  J. Shaw,et al.  Physical activity and the pelvic floor. , 2016, American journal of obstetrics and gynecology.

[10]  M. Stölzel,et al.  Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy : A Randomised Double-blind Multicentre Phase 3 B Study ( BESIDE ) , 2016 .

[11]  E. Hay-Smith,et al.  Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. , 2015, The Cochrane database of systematic reviews.

[12]  H. Kölbl,et al.  The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial , 2015, Therapeutic advances in urology.

[13]  C. De Nunzio,et al.  The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin? , 2015, Current opinion in urology.

[14]  Sean Nicholson,et al.  Economic Burden of Urgency Urinary Incontinence in the United States: A Systematic Review , 2014, Journal of managed care pharmacy : JMCP.

[15]  M. Carini,et al.  Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. , 2014, Urology.

[16]  A. Kanai,et al.  Urothelial mucosal signaling and the overactive bladder‐ICI‐RS 2013 , 2014, Neurourology and urodynamics.

[17]  G. Guyatt,et al.  What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women , 2014, European urology.

[18]  D. de Ridder,et al.  Long‐term follow‐up of sacral neuromodulation for lower urinary tract dysfunction , 2014, BJU international.

[19]  O. Yamaguchi,et al.  Functional consequences of chronic bladder ischemia , 2014, Neurourology and urodynamics.

[20]  K. Coyne,et al.  Comorbidities and personal burden of urgency urinary incontinence: a systematic review , 2013, International journal of clinical practice.

[21]  K. Burgio.  Update on Behavioral and Physical Therapies for Incontinence and Overactive Bladder: The Role of Pelvic Floor Muscle Training , 2013, Current Urology Reports.

[22]  Christopher J. Miller,et al.  Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. , 2013, The Journal of urology.

[23]  C. Elliott,et al.  Interstitial Cystitis and the Overlap With Overactive Bladder , 2012, Current Urology Reports.

[24]  C. Dubeau,et al.  The evaluation and treatment of nocturia: a consensus statement , 2011, BJU international.

[25]  K. Peters,et al.  Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. , 2010, The Journal of urology.

[26]  R. Freeman,et al.  An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, Neurourology and urodynamics.

[27]  C. Dumoulin,et al.  Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. , 2010, The Cochrane database of systematic reviews.

[28]  S. Shobeiri,et al.  Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. , 2009, The Journal of urology.

[29]  E. Vittinghoff,et al.  Weight loss to treat urinary incontinence in overweight and obese women. , 2009, The New England journal of medicine.

[30]  Amy M. Clobes,et al.  Urethral circular smooth muscle in young and old women. , 2008, American journal of obstetrics and gynecology.

[31]  D. Newman,et al.  Clinical Evaluation of the Pelvic Floor Muscles , 2008 .

[32]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[33]  H. Dallosso,et al.  Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. , 2006, Age and ageing.

[34]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[35]  P. Culligan,et al.  Urethral Sphincter Morphology in Women With Detrusor Instability , 2002, Obstetrics and gynecology.

[36]  P. Abrams,et al.  How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.

[37]  Finkbeiner,et al.  The pharmacological treatment of urinary incontinence , 1999, BJU international.

[38]  A. Brading.  A myogenic basis for the overactive bladder. , 1997, Urology.

[39]  W. D. de Groat,et al.  A neurologic basis for the overactive bladder. , 1997, Urology.